UPDATE: Citigroup Raises PT to $89 on DaVita

Citigroup raises its price target on Neutral-rated DaVita DVA to $89 from $87 on on broader market valuation considerations following the company's integrated care ESRD opportunity. Citigroup says, "We believe integrated care could theoretically boost DVA's earnings power by 10% but only once ALL U.S. dialysis patients are enrolled, a process that we doubt could be completed sooner than 2016 or 2017. DVA remains an "S&P stock" in our opinion, rated Neutral. We are raising our PT to $89, due entirely to an increase in broader market valuations (S&P500 +13% since out last update)." DVA closed at $85.48 a share on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsCitigroup
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!